Published in Blood on September 15, 1995
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma (2014) 1.59
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood (2006) 1.30
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood (2008) 1.25
Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol (2009) 1.21
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06
Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol (2015) 0.99
Radiation associated tumors following therapeutic cranial radiation. Surg Neurol Int (2012) 0.92
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica (2015) 0.91
Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis (2014) 0.90
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res (2015) 0.89
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Des Devel Ther (2016) 0.83
Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep (2009) 0.80
Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clin Exp Metastasis (2013) 0.80
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. Ann Hematol (2016) 0.78
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol (2014) 0.78
Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2014) 0.78
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica (2015) 0.77
Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol (2016) 0.75
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A (2001) 11.06
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 3.44
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia (2012) 2.80
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med (2001) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
Blunt tracheobronchial injuries: treatment and outcomes. Ann Thorac Surg (2001) 2.41
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia (1997) 2.26
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14
Afferent and efferent innervation of the cat cochlea: quantitative analysis with light and electron microscopy. J Comp Neurol (1990) 2.12
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87
Corynebacterium vaginale vaginitis. Review of the literature and presentation of data based on vaginal cultures from 1,008 patients. Am J Obstet Gynecol (1972) 1.87
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica (2000) 1.81
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia (2003) 1.76
Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics (2004) 1.72
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res (2001) 1.71
Non-randomized controls in cancer clinical trials. N Engl J Med (1974) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol (1997) 1.60
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia (2008) 1.53
Temperament, social competence, and adrenocortical activity in preschoolers. Dev Psychobiol (1997) 1.52
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood (1988) 1.51
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant (2004) 1.50
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood (1990) 1.49
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia (2012) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med (1995) 1.48
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood (1992) 1.48
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog? Ann Bot (2010) 1.47
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma (1993) 1.45
Separation and collection of leukocytes. Cancer Res (1965) 1.45
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol (2001) 1.42
Angiogenesis and leukemia. Leuk Res (2001) 1.42
Factors related to length of complete remission in adult acute leukemia. Cancer (1980) 1.42
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia (2007) 1.42
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med (1992) 1.41
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood (1985) 1.39